

vaccibody

Vaccibody AS


ICCS BIO in Philadelphia

June 3, 2019

Martin Bonde, PhD

CEO

mbonde@Vaccibody.com



Vaccibody AS in summary

- Founded in 2007 in Oslo, Norway
- Privately held clinical stage immuno-oncology company, spun-out from Oslo University, 24 employees
- Proprietary, patented vaccine technology
- Leader in the field of cancer neoantigen vaccines
- Experienced, international management team with oncology expertise and biotech pedigree driving development



Martin Bonde,
CEO



Agnete B. Frederiksen,
Founder, President and CSO




Mads B. Axelsen,
CMO



Mette Husbyn,
CTO



Vaccibody – Proprietary vaccine technology platform, uniquely suited for personalisation, including a strong rapid and long-lasting immune response

The Vaccibody technology platform is based on the concept of **targeting antigen to antigen presenting cells** in order to create more efficacious vaccines.



Vaccibody pipeline – two expanding programmes with high quality international collaborators and several shots on goal

| PROGRAM | DISCOVERY | PRE-CLINICAL | PHASE I | PHASE II | PHASE III |
|---|-------------------------------|--------------|---------|----------|-----------|
| MELANOMA LUNG (NSCLC) BLADDER RENAL HEAD AND NECK | VB10.NEO | | | | |
| HEAD AND NECK | VB10.NEO + NKTR-214 | | NEKTAR® | | |
| PRECANCEROUS CERVICAL LESIONS | VB10.16 | | | | |
| CERVICAL | VB10.16 + Atezolizumab (CPI)* | | Roche | | |



*Tecentriq® (Atezolizumab) is Roche's proprietary anti-PD-L1 checkpoint inhibitor (CPI)

Vaccibody aims to be best-in-class in personalized vaccines

Uniquely positioned and well-differentiated from competitors

VB10.NEO specific
proprietary selection
method: NeoSELECT™

- Robust, rapid, cost-effective manufacturing
- Stable, safe DNA plasmid format
- Hold up to 40 neoepitopes
- Needle-free delivery
- Rapid, strong, long-lasting
- Broad and CD8 dominated



1. Tumour biopsy
and sequencing



2. Neoepitope
selection



3. Vaccine
manufacturing
(n=1)




4. Vaccine
administration and
immunogenicity



Rapid, cost-effective, efficacious

Vaccibody in a nut shell

- Vaccibody has a proprietary vaccine technology platform used to create two clinical stage lead products:
 - Simple and robust technology; cost-effective; faster, stronger, longer lasting, and broader immune responses
 - Uniquely suited for personalized cancer treatment
- VB10.NEO – Personalized Therapeutic Neoantigen DNA Vaccine
 - Ongoing basket trial in five cancer indications
 - A proven robust and cost-effective manufacturing method
 - **Clinical collaboration with Nektar Therapeutics. Expected start Q3 2019**
- VB10.16 – Off-the-shelf Therapeutic Cancer DNA Vaccine against HPV16 induced malignancies
 - Clinical data provides strong proof-of-principle for the Vaccibody platform
 - Proven immunogenicity and clinical efficacy in phase I/IIa in precancerous cervical cancer (CIN)
 - Strong scientific rationale and evidence in support of combination with anti-PD-L1
 - **Deal with Roche for clinical supply of anti-PD-L1 (Atezolizumab) in cervical cancer study. Expected to start Q1 2020.**



Looking to explore the full potential of the Vaccibody technology with partners

vaccibody

www.vaccibody.com